A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Authors
Keywords
-
Journal
BLOOD
Volume 120, Issue 3, Pages 552-559
Publisher
American Society of Hematology
Online
2011-12-20
DOI
10.1182/blood-2011-06-360552
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
- (2011) W. G. Wierda et al. BLOOD
- Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
- (2011) G. J. Morgan et al. BLOOD
- Monoclonal antibodies in the treatment of multiple myeloma
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
- (2010) J. A. Zonder et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Antibody-maytansinoid conjugates for the treatment of myeloma
- (2010) Robert J. Lutz et al. mAbs
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death
- (2009) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
- (2009) Ingemar Turesson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Anti-CD20 monoclonal antibody therapy in multiple myeloma
- (2008) Prashant Kapoor et al. BRITISH JOURNAL OF HAEMATOLOGY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started